Management of diabetes mellitus: Defining the role of insulin lispro mix75/25 (Humalog® Mix75/25™)

Disease Management and Health Outcomes

Volumn 9, Issue 12, 2001, Pages 711-730

  Culy, Christine R ^a   Jarvis, Blair ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Diabetes mellitus; Disease management; Humalog Mix25; Review on treatment

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; HUMAN INSULIN; INSULIN; INSULIN LISPRO; INSULIN LISPRO MIX75/25; ISOPHANE INSULIN; UNCLASSIFIED DRUG;

DIABETES MELLITUS; DIET THERAPY; DRUG EFFICACY; DRUG FORMULATION; DRUG MIXTURE; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INJECTION; INSULIN DEFICIENCY; INSULIN RESISTANCE; MORTALITY; REVIEW; VASCULAR DISEASE;

EID: 0035685655     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200109120-00005     Document Type: Review

References (102)

1. Long-term complications of diabetes mellitus
2. 1998 Clinical practice guidelines for the management of diabetes in Canada
3. Prevention and treatment of the complications of diabetes mellitus
4. Morbidity and mortality in diabetics in the Framingham population: Sixteen year follow-up study
5. Direct and indirect costs of cardiovascular and cerebrovascular complications of type II diabetes
6. Relationship between diabetes and mortality: A population study using record linkage
7. Report of the expert committee on the diagnosis and classification of diabetes mellitus
8. Pharmacologic therapy for type 2 diabetes mellitus
9. Type 2 diabetes mellitus: Update on diagnosis, pathophysiology, and treatment
10. Type 2 diabetes: An overview
11. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus
12. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: The Third National Health and Nutrition Examination Survey, 1988-1994
13. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in the U.S. population aged 20-74 yr
14. Epidemiology of type II diabetes: An international perspective
15. Diabetes trends in the U.S.: 1990-1998
16. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults
17. Epidemiology of diabetes mellitus among the elderly in the United States
18. Screening for type 2 diabetes
19. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33
20. A desktop guide to Type 2 diabetes mellitus: European Diabetes Policy Group 1999
21. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance
22. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data
23. American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles
24. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies
25. The changing classification and diagnosis of diabetes: New classification is based on pathogenesis, not insulin dependence
26. Standards of medical care for patients with diabetes mellitus
27. The economic impact of diabetes
28. Health care expenditures for people with diabetes mellitus, 1992
29. Economic consequences of diabetes mellitus in the U.S. in 1997
30. Medical care expenditures for diabetes, its chronic complications, and its comorbidities
31. Direct medical costs of complications resulting from type 2 diabetes in the U.S.
32. Cost of illness of adult diabetes mellitus underestimated if comorbidity is not considered
33. The economic cost of diabetes in Canada, 1998
34. The European Association for the Study of Diabetes Annual Meeting, 1998: The UK Prospective Diabetes Study and other topics in type 2 diabetes
35. Lifetime benefits and costs of intensive therapy as practiced in the Diabets Control and Complications Trial
36. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: Economic analysis alongside randomised controlled trial (UKPDS 41)
37. A desktop guide to Type 1 (insulin-dependent) diabetes mellitus
38. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
39. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
40. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
41. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients
42. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy
43. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective study (UKPDS:23)
44. Diabetic dyslipidaemia: Current treatment recommendations
45. Drug treatment of hypertension complicating diabetes mellitus
46. Management of type 2 diabetes mellitus and cardiovascular risk: Lessons from intervention trials
47. Cholerterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
48. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
49. Tight blood pressure control and risk of macrovascular and micorvascular complications in type 2 dibetes (UKPDS 38)
50. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria
51. Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11-year follow-up
52. Drug therapy of postprandial hyperglycaemia
53. The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease
54. The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications
55. Diet and diabetes
56. Ten-year experience with exercise-based outpatient life-style modification program in the treatment of diabetes mellitus
57. Diabetes mellitus and exercise
58. Exercise in individuals with IDDM
59. Nutrition recommendations and principles for people with diabetes mellitus
60. Oral antidiabetic agents: A guide to selection
61. Recent developments and emerging therapies for type 2 diabetes mellitus
62. Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus
63. Insulins: General statement
64. Humalog Mix75/25™
65. B29]-human insulin analogue
66. Type 1 diabetes mellitus and the use of flexible insulin regimens
67. Overview of current therapeutic options in type 2 diabetes. Rationale for combining oral agents with insulin therapy
68. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus
69. The use of fixed-mixture insulins in clinical practice
70. Recombinant human insulin analogues: Recommendations for optimal use
71. Insulin analogues and management of diabetes mellitus
72. Insulin lispro: A review of its pharmacological properties and therapeutic use in the management of diabetes mellitus
73. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients
74. Premixed formulations of insulin lispro: Activity profiles in type 1 diabetic patients
75. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin
76. Humalog Mix25 offers better mealtime glycemic control in patients with type 1 or type 2 diabetes
77. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro Mix25 and insulin lispro Mix50
78. Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients
79. Improved postprandial glycemic control during treatment with Humalog Mix25, or a novel protamine-based insulin lispro formulation
80. Effects of acute physical exercise on blood glucose in patients with type 2 diabetes on treatment with Humalog Mix25
81. Postprandial blood glucose excursions are smaller with Humalog Mix25 than with Humulin 30/70
82. Humalog Mix25 twice daily improves glycemic control compared to NPH twice daily in patients with type 2 diabetes
83. Humalog Mix25 twice daily versus glibenclamide improves glycemic control in patients with type 2 diabetes
84. Initiation of Humalog Mix25 therapy improves glycemic control in patients with type 2 diabetes and inadequacy of oral agent combination therapy
85. Initiation of insulin treatment with pre-meal or post-meal Humalog Mix25 twice daily improves glycemic control in elderly patients with type 2 diabetes who are not well-controlled with sulfonylureas
86. Reduced nocturnal hypoglycaemia with twice daily Humalog Mix25 compared to human insulin 30/70 in patients with type 2 diabetes
87. Postprandial and preprandial administration of Humalog Mix25 provide comparable glycemic control
88. Comparable glycemic control with pre-meal or postmeal injection of Humalog Mix25 in elderly patients with type 2 diabetes
89. Pre-meal and post-meal use of Humalog Mix25 in elderly patients with type 2 diabetes and oral treatment inadequacy with sulfonylureas
90. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes
91. Clinical outcomes with insulin lispro compared with regular human insulin: A metaanalysis
92. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment
93. Hypoglycemia and insulin analogues: Is there a reduction in the incidence?
94. Interval between insulin injection and breakfast in diabetes
95. Interval between insuiln injection and eating in relation to blood glucose control in adult diabetics
96. Influence of intensive diabetes treatment on quality-of-life outcomes in the Diabetes Control and Complications Trial
97. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37)
98. The impact of diabetic complications on the quality of life of patients with type 2 diabetes
99. The economic value of a new insulin preparation, Humalog Mix 25: Measured by a willingness-to-pay approach
100. Patients value the clinical characteristics and convenience of Humalog Mix25: Results of a Willingness To Pay study in patients with type 2 diabetes